Barton Ford Haynes, MD

Professor of Medicine
Frederic M. Hanes Professor of Medicine
Director of the Human Vaccine Institute in the Department of Medicine
Research Professor of Global Health
Professor of Immunology
Member of the Duke Cancer Institute
Member of the Duke Human Vaccine Institute
Campus mail 106 Research Drive, MSRBII 4090, Durham, NC 27710
Phone (919) 684-5384
Email address hayne002@mc.duke.edu

The Haynes lab is studying host innate and adaptive immune responses to the human immunodeficiency virus (HIV), tuberculosis (TB), and influenza in order to find the enabling technology to make preventive vaccines against these three major infectious diseases.

Mucosal Immune Responses in Acute HIV Infection

The Haynes lab is working to determine why broadly neutralizing antibodies are rarely made in acute HIV infection (AHI), currently a major obstacle in the development of an HIV vaccine. The lab has developed a novel approach to define the B cell repertories in AHI in order to find neutralizing antibodies against the virus. This approach uses linear Immunoglobulin (Ig) heavy and light chain gene expression cassettes to express Ig V(H) and V(L) genes isolated from sorted single B cells as IgG1 antibody without a cloning step. This strategy was used to characterize the Ig repertoire of plasma cells/plasmablasts in AHI and to produce recombinant influenza mAbs from sorted single human plasmablasts after influenza vaccination.

The lab is also studying the earliest effect HIV-1 has on B cells. Analyzing blood and gut-associated lymphoid tissues (GALT) during acute HIV infection, they have found that as early as 17 days after transmission HIV-1 induces B cell class switching and 47 days after transmission, HIV-1 causes considerable damage to GALT germinal centers. They found that in AHI, GALT memory B cells induce polyclonal B cell activation due to the presence of HIV-1-specific, influenza-specific, and autoreactive antibodies. The team concluded from this study that early induction of polyclonal B cell differentiation, along with follicular damage and germinal center loss, may explain why HIV-1 induced antibody responses decline rapidly during acute HIV infection and why plasma antibody responses are delayed.

The lab is also looking at ways of generating long-lived memory B cell responses to HIV infection, another major hurdle in the development of a successful HIV-1 vaccine. The lab has found that in HIV-1 gp120 envelope vaccination and chronic HIV-1 infection, HIV-1 envelope induces predominantly short-lived memory B cell-dependent plasma antibodies.

Immunogen Design

To overcome the high level of genetic diversity in HIV-1 envelope genes, the Haynes lab is developing strategies to induce antibodies that cross-react with multiple strains of HIV. The lab has designed immunogens based on transmitted founder Envs and mosaic consensus Envs in collaboration with Dr. Bette Korber at Los Alamos National Laboratory. These immunogens are designed to induce antibodies that cross-react with a multiple subtype Env glycoproteins. The goal is to determine if cross-reactive mAbs to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced. The team recently characterized a panel of ten mAbs that reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env protein. Two of the mAbs cross-reacted with all tested Env proteins, including SIVcpzUS Env and bound Env proteins with high affinity.

Mucosal Immune Responses in TB and Influenza

The Haynes lab is helping to develop novel approaches to TB vaccine development. The current therapeutic vaccine for TB, called BCG, may prevent complications from TB in children, but offers little protection against infection and disease in adults. The lab is focused on using live attenuated Mycobacterium tuberculosis mutants as vaccine candidates and is currently evaluating this approach in non-human primate studies. As part of the DHVI Influenza program, they are studying the B cell response to influenza in order to generate a “universal” flu vaccine. They are currently trying to express more highly conserved influenza antigens in recombinant vesicular stomatitis virus (rVSV) vectors in order to elicit robust T cell and antibody responses to those antigens.

Education and Training

  • M.D., Baylor University, 1973

Publications

Haynes, BF. "New approaches to HIV vaccine development." Current opinion in immunology 35 (August 2015): 39-47. (Review)

PMID
26056742
Full Text

Williams, WB, Liao, H-X, Moody, MA, Kepler, TB, Alam, SM, Gao, F, Wiehe, K, Trama, AM, Jones, K, Zhang, R, Song, H, Marshall, DJ, Whitesides, JF, Sawatzki, K, Hua, A, Liu, P, Tay, MZ, Seaton, KE, Shen, X, Foulger, A, Lloyd, KE, Parks, R, Pollara, J, Ferrari, G, Yu, J-S, Vandergrift, N, Montefiori, DC, Sobieszczyk, ME, Hammer, S, Karuna, S, Gilbert, P, Grove, D, Grunenberg, N, McElrath, MJ, Mascola, JR, Koup, RA, Corey, L, Nabel, GJ, Morgan, C, Churchyard, G, Maenza, J, Keefer, M, and Graham, BS et al. "HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies." Science (New York, N.Y.) 349, no. 6249 (August 2015): aab1253-.

PMID
26229114
Full Text

Hart, BE, Asrican, R, Lim, S-Y, Sixsmith, JD, Lukose, R, Souther, SJR, Rayasam, SDG, Saelens, JW, Chen, C-J, Seay, SA, Berney-Meyer, L, Magtanong, L, Vermeul, K, Pajanirassa, P, Jimenez, AE, Ng, TW, Tobin, DM, Porcelli, SA, Larsen, MH, Schmitz, JE, Haynes, BF, Jacobs, WR, Lee, S, and Frothingham, R. "Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors." Clinical and vaccine immunology : CVI 22, no. 7 (July 2015): 726-741.

PMID
25924766
Full Text

Permar, SR, Fong, Y, Vandergrift, N, Fouda, GG, Gilbert, P, Parks, R, Jaeger, FH, Pollara, J, Martelli, A, Liebl, BE, Lloyd, K, Yates, NL, Overman, RG, Shen, X, Whitaker, K, Chen, H, Pritchett, J, Solomon, E, Friberg, E, Marshall, DJ, Whitesides, JF, Gurley, TC, Von Holle, T, Martinez, DR, Cai, F, Kumar, A, Xia, S-M, Lu, X, Louzao, R, Wilkes, S, Datta, S, Sarzotti-Kelsoe, M, Liao, H-X, Ferrari, G, Alam, SM, Montefiori, DC, Denny, TN, Moody, MA, Tomaras, GD, Gao, F, and Haynes, BF. "Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission." Journal of Clinical Investigation 125, no. 7 (July 2015): 2702-2706.

PMID
26053661
Full Text

Nicely, NI, Wiehe, K, Kepler, TB, Jaeger, FH, Dennison, SM, Rerks-Ngarm, S, Nitayaphan, S, Pitisuttithum, P, Kaewkungwal, J, Robb, ML, O'Connell, RJ, Michael, NL, Kim, JH, Liao, H-X, Munir Alam, S, Hwang, K-K, Bonsignori, M, and Haynes, BF. "Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee." EBioMedicine 2, no. 7 (July 2015): 713-722.

PMID
26288844
Full Text

Haynes, BF, and Bradley, T. "Broadly Neutralizing Antibodies and the Development of Vaccines." JAMA 313, no. 24 (June 2015): 2419-2420.

PMID
26103022
Full Text

Hulot, SL, Korber, B, Giorgi, EE, Vandergrift, N, Saunders, KO, Balachandran, H, Mach, LV, Lifton, MA, Pantaleo, G, Tartaglia, J, Phogat, S, Jacobs, B, Kibler, K, Perdiguero, B, Gomez, CE, Esteban, M, Rosati, M, Felber, BK, Pavlakis, GN, Parks, R, Lloyd, K, Sutherland, L, Scearce, R, Letvin, NL, Seaman, MS, Alam, SM, Montefiori, D, Liao, H-X, Haynes, BF, and Santra, S. "Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost." Journal of virology 89, no. 12 (June 2015): 6462-6480.

PMID
25855741
Full Text

Zhou, T, Lynch, RM, Chen, L, Acharya, P, Wu, X, Doria-Rose, NA, Joyce, MG, Lingwood, D, Soto, C, Bailer, RT, Ernandes, MJ, Kong, R, Longo, NS, Louder, MK, McKee, K, O'Dell, S, Schmidt, SD, Tran, L, Yang, Z, Druz, A, Luongo, TS, Moquin, S, Srivatsan, S, Yang, Y, Zhang, B, Zheng, A, Pancera, M, Kirys, T, Georgiev, IS, Gindin, T, Peng, H-P, Yang, A-S, NISC Comparative Sequencing Program, , Mullikin, JC, Gray, MD, Stamatatos, L, Burton, DR, Koff, WC, Cohen, MS, Haynes, BF, Casazza, JP, and Connors, M et al. "Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors." Cell 161, no. 6 (June 2015): 1280-1292.

PMID
26004070
Full Text

Chuang, G-Y, Zhang, B, McKee, K, O'Dell, S, Kwon, YD, Zhou, T, Blinn, J, Lloyd, K, Parks, R, Von Holle, T, Ko, S-Y, Kong, W-P, Pegu, A, Wang, K, Baruah, K, Crispin, M, Mascola, JR, Moody, MA, Haynes, BF, Georgiev, IS, and Kwong, PD. "Eliminating antibody polyreactivity through addition of N-linked glycosylation." Protein Science : A Publication of the Protein Society 24, no. 6 (June 2015): 1019-1030.

PMID
25800131
Full Text

Fernández-Tejada, A, Haynes, BF, and Danishefsky, SJ. "Designing synthetic vaccines for HIV." Expert review of vaccines 14, no. 6 (June 2015): 815-831. (Review)

PMID
25824661
Full Text

Pages